Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
Status:
Completed
Trial end date:
2018-01-20
Target enrollment:
Participant gender:
Summary
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy
obtaining sustained virologic response (SVR) in 77% of naïve patients with genotype 1-3
Studies rarely address the issues of improving host factors. The current study examines
whether adding vitamin D with Peg/RBV, a potent immunomodulator, could improve viral
response(SVR)compared to Peg/RBV.